Performance analysis of Actinium Pharmaceuticals (ATNM)
Annual Return
Over the past 3 years, ATNM has had an average annual return of -50.32%, underperforming the benchmark SPY, which returned +19.31% annual.
Over the past 5 years, ATNM has had an average annual return of -34.52%, underperforming the benchmark SPY, which returned +12.55% annual.
Over the past 10 years, ATNM has had an average annual return of -33.64%, underperforming the benchmark SPY, which returned +14.95% annual.
Since Dec 27, 2012, ATNM has had an average annual return of -25.16%, underperforming the benchmark SPY, which returned +14.93% annual.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -35.10% | +7.86% | -75.20% | -52.30% | +77.17% | -22.91% | +19.27% | -43.68% | -41.72% | -24.10% | -72.91% | -45.16% |
| 2014 | 2013 | 2012 | |||||||||
| -0% | +292.67% | +0% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -14.57% | +1.55% | -15.65% | +11.76% | +13.36% | -22.14% | -10.09% | -35.10% | |||||
| 2025 | -7.86% | -0.78% | +39.84% | -5.59% | +1.18% | -9.06% | +16.40% | +9.39% | -10.10% | -10.67% | -3.46% | -1.63% | +7.86% |
| 2024 | +5.93% | +58.53% | -8.23% | -1.67% | +5.84% | -9.22% | -6.45% | -71.26% | -5.43% | -4.31% | -20.00% | -12.50% | -75.20% |
| 2023 | +10.01% | -17.67% | -2.05% | -6.86% | -5.73% | -10.57% | -4.06% | -15.55% | -1.50% | -5.78% | -17.90% | +10.90% | -52.30% |
| 2022 | -10.03% | -0.17% | -5.33% | +16.99% | -7.67% | -12.88% | +2.53% | +42.52% | +4.99% | +83.48% | -18.25% | -3.78% | +77.17% |
| 2021 | +1.04% | +2.28% | -5.47% | +0.53% | +6.52% | -3.03% | -15.81% | -8.72% | +45.74% | -11.43% | -8.66% | -16.13% | -22.91% |
| 2020 | +15.14% | -5.14% | -18.53% | -4.64% | +15.17% | +65.28% | +63.70% | -51.93% | +16.57% | +2.79% | +10.44% | -29.09% | +19.27% |
| 2019 | +43.41% | +5.41% | -17.95% | -36.47% | +6.59% | -24.32% | -5.30% | -1.29% | -0% | +8.74% | +7.98% | -19.28% | -43.68% |
| 2018 | +6.01% | -38.91% | -15.14% | -1.89% | +7.54% | +66.23% | +2.18% | -2.13% | +15.94% | -18.74% | -3.66% | -33.38% | -41.72% |
| 2017 | +21.16% | +33.01% | +7.10% | +0% | -5.30% | -14.69% | -45.00% | -9.08% | -5.73% | +8.66% | +10.42% | -3.76% | -24.10% |
Drawdown analysis of Actinium Pharmaceuticals (ATNM)
The maximum drawdown for the ATNM was -99.78%, occurring on Jul 20, 2026. This drawdown has not yet recovered.
The current ATNM drawdown is -99.78%.
Since Dec 27, 2012 ATNM has experienced the following drawdowns:
- 50% or more: 2 times
- 40% or more: 2 times
- 30% or more: 3 times
- 20% or more: 3 times
- 10% or more: 5 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.78% | Apr 23, 2014 | 3077 | Jul 20, 2026 | Ongoing | Ongoing | Ongoing |
| -58.67% | Mar 20, 2013 | 50 | May 31, 2013 | 134 | Dec 10, 2013 | 184 |
| -32.13% | Dec 10, 2013 | 9 | Dec 23, 2013 | 53 | Mar 12, 2014 | 62 |
| -11.50% | Mar 25, 2014 | 1 | Mar 26, 2014 | 3 | Mar 31, 2014 | 4 |
| -10.70% | Apr 3, 2014 | 2 | Apr 7, 2014 | 11 | Apr 23, 2014 | 13 |
| -4.17% | Mar 14, 2014 | 2 | Mar 18, 2014 | 5 | Mar 25, 2014 | 7 |
| -0.40% | Mar 31, 2014 | 1 | Apr 1, 2014 | 1 | Apr 2, 2014 | 2 |